Keywords: sec, investigates, tkt, replagal, disclosures, usa-based, transkaryotic

SEC investigates TKT's Replagal disclosures

Article | 26 May 2003

USA-based Transkaryotic Therapies has fallen under the spotlight of a Securities and Exchange Commission investigation relating to disclosures and public ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Genzyme

Go to company listing

Related Drugs

Agalsidase Beta

Fabrazyme

Go to drug listing